Skip to main content

Clinical Trials: Solanezumab in Alzheimer's Disease

From Bloomberg:

Eli Lilly Shares Rise on Alzheimer’s Drug Hopes
By Drew Armstrong and Robert Langreth
Dec 6, 2011

[snip]

"Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s disease. Pfizer Inc. (PFE), Johnson & Johnson and Elan are testing bapineuzumab, a similar drug."

[snip]

Read the article

Comments

Popular posts from this blog

Welcome to Summer Session!

Summer Session begins next week for me. I am teaching several courses that I much enjoy: Introduction to Clinical Neuropsychology, Psychopharmacology, Cognitive, and Clinical Neuroscience. Let the sun shine and the coffee flow!

Welcome to Fall Semester!